Cabaletta Bio Receives FDA Orphan Drug Designation for CABA-201 in Systemic Sclerosis Treatment
Philadelphia-based biotechnology company, Cabaletta Bio, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for their investigational therapy, CABA-201, intended for the treatment of systemic sclerosis (SSc). This exciting development marks an important milestone in the company’s mission to develop groundbreaking targeted cell therapies for patients with autoimmune diseases.
CABA-201 is a fully human CD19-CAR T cell therapy that contains the 4-1BB molecule. The therapy is being developed specifically to target B cells, which play a crucial role in the development and progression of autoimmune diseases. By harnessing the power of CABA-201, Cabaletta Bio aims to restore self-tolerance and provide a potential curative treatment option for patients suffering from SSc.
The Orphan Drug Designation (ODD) granted by the FDA is a significant achievement for Cabaletta Bio and highlights the potential of CABA-201 in addressing the unmet medical needs of individuals with systemic sclerosis. ODD is granted to therapies that demonstrate promise in treating rare diseases affecting fewer than 200,000 individuals in the United States. By receiving this designation, Cabaletta Bio gains eligibility for various incentives, including tax credits, fee reductions, and a period of market exclusivity upon FDA approval.
The ODD for CABA-201 in the treatment of systemic sclerosis is part of the larger RESET (REstoring SElf-Tolerance) clinical trial program. This program encompasses four Phase 1/2 trials that aim to evaluate the safety and efficacy of CABA-201 across multiple autoimmune conditions. The Phase 1/2 RESET-SSc trial, specifically designed for systemic sclerosis, will further investigate the potential of CABA-201 in addressing this debilitating condition.
Systemic sclerosis, also known as scleroderma, is a complex autoimmune disease that affects the connective tissues and blood vessels in the body. It often leads to the thickening and hardening of the skin and can affect internal organs, causing a range of symptoms and complications. Currently, there are limited treatment options available for systemic sclerosis, making the development of innovative therapies like CABA-201 of utmost importance.
The granting of Orphan Drug Designation to CABA-201 emphasizes the significance of Cabaletta Bio’s commitment to developing novel cell therapies that target the underlying causes of autoimmune diseases. By addressing the dysregulated immune response seen in systemic sclerosis, CABA-201 holds the potential to revolutionize the treatment landscape for this rare and challenging condition.
Cabaletta Bio’s achievement in receiving FDA Orphan Drug Designation for CABA-201 is an encouraging step forward in the pursuit of curative therapies for autoimmune diseases. The RESET program, including the RESET-SSc trial, will continue to advance research and clinical evaluation, offering hope to patients suffering from systemic sclerosis and other related conditions.
Comments